Clinical trials and adverse event data found lymphoma and other cancer growth among some CAR-T cell medicines: Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Carvykti (ciltacabtagene autoleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
Weeks after infusion, patients might develop mature T cell malignancies, including tumors, the agency said April 18.
The agency’s investigation began in November. By January, the FDA quantified the probe and said it was reviewing 22 reports of patients contracting blood cancer. The FDA then called for safety labeling changes before increased mortality rates were discovered in March.
“Patients and clinical trial participants receiving treatment with these products should be monitored lifelong for secondary malignancies,” the FDA said April 18.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.